Keywords
Atorvastatin
Leukopenia
Cachexia
Anticancer agent
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To study the administration of atorvastatin on oral mucositis (OM), evaluating dosage, clinical status of the animals, maintenance of the leukocyte number and cachexia in a model of MO chemoinduced by the chemotherapy drug 5-Fluorouracil (5-FU). Methods: Thirty six wistar rats were divided into Control Group (CG): 5-FU + 0.9% Saline Solution; Group I (GI): 5-FU + 1mg of atorvastatin; Group II (GII): 5-FU + 5mg of atorvastatin and Group III (GIII): 5-FU + 10mg of atorvastatin. Results: Through histological analyzes, CG showed loss of lining epithelium; GI maintained the integrity of the lining epithelium, but thinner; GII presented the preserved lining epithelium and Group III maintained the thick lining epithelium. Global leukocyte count: CG was considered high; GI showed low counts; GII showed a decrease, and GIII maintained a leukogram within normal values. After induction of MO, intense cachexia and weight loss were observed in the CG; GI cachexia was less pronounced; and cachexia and weight loss were observed in Groups II and III, but this improved more rapidly, with a tendency toward weight gain. Conclusión: The preventive potential of atorvastatin in wistar rats was defined as a preventive and safer dose of 10 mg/kg/day.
References
ARAÚJO AA. et al. Azilsartan reduced TNF-α and IL-1β levels, increased IL-10 levels and upregulated VEGF, FGF, KGF, and TGF-α in an oral mucositis model. Plos One, 2015; 10(2).
ANDALIB S, et al. In vitro and in vivo delivery of atorvastatin: A comparative study of anti-inflammatory activity of atorvastatin loaded copolymeric micelles. J Biomater Appl, 2018; 32(8): 1127-1138.
AHMED AA, et al. α-Lipoic acid ameliorates oral mucositis and oxidative stress induced by methotrexate in rats. Histological and immunohistochemical study. Life Sci, 2017; 171:51-9.
AZEVEDO IM, et al. Effect of simvastatin in attenuation of mucositis induced by methotrexate in rats. J Surg Clin Res, 2010; 1:22-32.
BARBER C, et al. Comparing pain control and ability to eat and drink with standard therapy vs. Gelclair: a preliminary, double centre, randomized controlled trial on patients with radiotherapy induced oral mucositis. Support Care Cancer, 2007; 15(4):427 40.
CAMPOS MIC, et al. Oral mucositis in cancer treatment: natural history, prevention and treatment (Review). Mol Clin Oncol, 2014; 2(3):337-340.
CAMPOS MIC, et al. Atorvastatin and trans-caryophyllene for the prevention of leukopenia in an experimental chemotherapy model in Wistar rats. Mol Clin Oncol, 2015; 3(4):825-8.
CAMPOS MIC, et al. Induced oral mucositis in Wistar rats treated with different drugs: Preventive potential in cytokine production. Mol Clin Oncol, 2021; 14(6):127.
CINAUSERO CM, et al. New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front Pharmacol, 2017; 8:354.
CHAVELI-LÓPEZ B, BAGÁN-SEBASTIÁN JV. Treatment of oral mucositis due to chemotherapy. J Clin Exp Dent, 2016; 8(2):201-9.
DODD MJ, et al. Randomized clinical trial of the effectiveness of 3 commonly used mouthwashes to treat chemotherapy induced mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2000; 90(1):39 47.
DÖRR W, et al. Radiation induced changes in cellularity and proliferation in human oral mucosa. Int J Radiat Oncol Biol Phys, 2002; 52(4):911 7.
FERRO D, et al. Sinvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. J Am Coll Cardiol, 2000; 36(2):427-31.
HITOMI S, et al. [6]-gingerol and [6]-shogaol, active ingredients of the traditional Japanese medicine hangeshashinto, relief oral ulcerative mucositis-induced pain via action on Na(+) channels. Pharmacol Res, 2017; 117:288-302.
KANAGALINGAM J, et al. Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis Percep Tion (ADOPT) study. Support Care Cancer, 2018; 26(7):2191-2200.
KIRK J, et al. Text mining-based in silico drug discovery in oral mucositis caused by high-dose cancer therapy. Support Care Cancer, 2018; 26(8):2695-705.
KOWANKO I, et al. The effec¬tiveness of strategies for preventing and treating chemotherapy and radiation induced oral mucositis in patients with cancer. Australia: Joanna Briggs Institute for Evidence Based Nursing and Midwifery, Systemic Review, 1998; 2.
LAUF U, et al. Inhibition of 3-Hydroxy-3-methylglutaryl (HMG) - CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem, 1997; 12, 272(50):31725-9.
LEGOUTÉ F, et al. Low-level laser therapy in treatment of chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial. Radiat Oncol, 2019; 14(1):83.
MEDEIROS CA, et al. Effect of atorvastatin on 5-fluorouracil experimental oral mucositis. Cancer Chemother Pharmacol, 2011; 67(5):1085-100.
ONSENG K, et al. Beneficial effect of adjuvant melatonin in minimizing oral mucositis complications in head and neck cancer patients receiving concurrent chemoradiation. J Altern Complement Med, 2017; 23(12):957-6.
SOLHEIM S, et al. Seljeflot I, Arnesen H, EIkvar L. Reduced levels of TNF- in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. Atheroclerosis, 2001; 157(2):411-5.
SONIS ST. An animal model for mucositis induced by cancer chemotherapy. Oral Surgery Oral Med Oral Pathol, 1990; 69(4):437-443.
SONIS ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy induced stomatotoxicity. Oral Oncol, 1998; 34(1):39 43.
SONIS ST. New thoughts on the initiation of mucositis. Oral Dis, 2010; 16(7):597-600.
SONIS ST, Villa A. Phase II investigational oral drugs for the treatment of radio/chemotherapy induced oral mucositis. Expert Opin Investig Drugs, 2018; 27(2):147-54.
SOFIS MJ, et al. KU32 prevents 5-fluorouracil induced cognitive impairment. Brain Res, 2017; 30:186-190.
SHIMAMURA Y, et al. Takeuchi I, Terada H, Makino K. A mouse model for oral mucositis induced by cancer chemotherapy. Anticancer Res, 2018; 38(1):307-312.
STEINMANN D, et al. Eilers V, Beynenson D, Buhck H, Fink M. Effect of Traumeel Son pain and discomfort in
radiation induced oral mucositis: a preliminary observational study. Altern Ther Health Med, 2012; 18(4):12-8.
VIEIRA WDA, et al. Modelo experimental de Mucosite Oral e intestinal em ratos Wistar. Rev Int Est Exp, 2018; 10:01-60.
WALLADBEGI J, et al. Smith SA, Grayson AK, Murdoch C, Jontell M, Colley HE. Cooling of the oral mucosa to prevent adverse effects of chemotherapeutic agents: An in vitro study. J Oral Pathol Med, 2018; 47(5):477-83.
WHITTAKER AL, et al. Wirthensohn MG. Effects of commercially produced almond by-products on chemotherapy-induced mucositis in rats. J Gastrointest Pathophysiol, 2017; 8(4):176-87.